Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2021-04-26 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司章程（2021.04）
Governance Information Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司章程" which translates to the Articles of Association or Company Bylaws of Beijing SL Pharmaceutical Co., Ltd. It contains detailed provisions about the company's organization, shareholder rights, board of directors, management, shareholder meetings, voting procedures, share issuance, and other governance matters. The content is focused on the internal rules and governance structure of the company rather than financial results, audit opinions, or announcements. There is no indication that this is an annual report, earnings release, or any other financial or regulatory filing. The document is a governance document outlining the company's internal rules and practices, which fits the definition of Governance Information (CGR).
2021-04-26 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a special explanation report regarding the use of funds by controlling shareholders and other related parties of Beijing SL Pharmaceutical Co., Ltd. It references an audit report issued by Da Hua Certified Public Accountants for the fiscal year ending December 31, 2020. The document includes a detailed summary table of fund occupation by related parties for the year 2020. It is issued in compliance with regulations from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is not a full annual report or audit report but a specialized statement related to related-party fund occupation, which is a type of audit-related disclosure. It is not a mere announcement or certification but contains substantive audited financial data and explanations. Therefore, it fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and related disclosures excluding full annual reports. FY 2020
2021-04-26 Chinese
独立董事对担保等事项的独立意见
Governance Information Classification · 95% confidence The document is an independent opinion report from the independent directors of Beijing Shuanglu Pharmaceutical Co., Ltd. It covers multiple governance-related topics such as profit distribution plans, internal control self-evaluation, appointment of the audit firm, short-term investment using own funds, external guarantees and related party transactions, and board election matters. The document references compliance with regulatory guidelines and company bylaws, and it is focused on governance and oversight opinions rather than presenting financial statements or audit results themselves. The document length is 3839 characters, which is relatively short and consistent with an opinion or governance report rather than a full annual or interim report. It does not contain financial statements or detailed financial data, nor is it a transcript or presentation. The content aligns best with a Governance Information (CGR) filing, as it details governance practices, board opinions, and compliance with governance regulations.
2021-04-26 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2020 Annual Work Report" for Beijing SL Pharmaceutical Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters including investment, profit distribution, internal control, audit firm appointment, related party transactions, and accounting policy changes for the year 2020. The content is a detailed report of the independent director's duties and opinions over the fiscal year 2020, which aligns with a management or board-related report rather than a full annual report or audit report. It is not a transcript, earnings release, or a simple announcement. The document focuses on board/management information, specifically the independent director's report on their duties and opinions for the year. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (5987 characters) and detailed content support this classification with high confidence.
2021-04-26 Chinese
北京双鹭药业股份有限公司关于使用自有资金进行短期风险投资事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the use of its own funds for short-term risk investment. It details the investment purpose, amount, objects, internal control system, risk control measures, and opinions from independent directors and the supervisory board. The document is a formal public announcement about a financing/investment activity by the company, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather describes a capital use decision and related governance. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 2919 characters, which is consistent with an announcement rather than a full report.
2021-04-26 Chinese
北京双鹭药业股份有限公司关于监事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the re-election of the supervisory board members (监事会换届选举) of Beijing SL Pharmaceutical Co., Ltd. It details the nomination of candidates for the new supervisory board, their qualifications, and the process for election at the shareholders' meeting. There is no financial data, audit information, or report content. The document is a formal announcement about changes in the company's supervisory board, which falls under management or board information disclosures. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2021-04-26 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.